Drug intelligence / Profile preview

IVX-A12

Development stage
Phase 2
Lead developer
AstraZeneca
Modality
Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

IVX-A12 is a bivalent, virus-like particle (VLP) vaccine candidate designed to protect against both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Developed by Icosavax (acquired by AstraZeneca), the vaccine utilizes computationally designed protein nanoparticle technology originating from the University of Washington. It is intended for older adults, a population at high risk for severe respiratory infections, and aims to be the first combination vaccine to address both pathogens simultaneously. The vaccine is currently Phase III-ready.

Brand names
IVX-A12IVX-A-12IVX-A 12
Other names
RSV + hMPV combination vaccineRSV/hMPV VLP vaccineinvestigational RSV and hMPV vaccine
02

Targets

RSV F (Respiratory syncytial virus fusion protein)hMPV preF (Human metapneumovirus prefusion fusion glycoprotein)

Beyond the preview

Go deeper on IVX-A12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVX-A12.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call